Biomarin Pharmaceutical Intrinsic Value Calculator – Truist Financial Corp Holds Over $346K Stake in BioMarin Pharmaceutical
November 15, 2023
🌥️Trending News
BIOMARIN ($NASDAQ:BMRN): BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for people with serious and life-threatening diseases. It focuses on developing and commercializing therapeutics for rare and ultra-rare diseases, such as hemophilia, lysosomal storage disorders, and other genetic diseases. The company has recently seen success in the development of treatments for rare diseases, such as its recently approved treatment for mucopolysaccharidosis type VI, which is an ultra-rare genetic disorder. The company’s continued success and potential for future innovations is likely to make it an attractive investment option for a variety of investors.
Share Price
On Monday, BIOMARIN PHARMACEUTICAL stock opened at $83.2 and closed at $83.4, a decrease of 0.7% from last closing price of 84.0. BIOMARIN PHARMACEUTICAL is a biotechnology company that is focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare diseases. With its strong focus on research and development, BIOMARIN PHARMACEUTICAL has established a portfolio of innovative treatments for a number of rare disorders. The company’s pipeline consists of several promising compounds and treatments that are expected to benefit patients in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biomarin Pharmaceutical. More…
| Total Revenues | Net Income | Net Margin |
| 2.31k | 147.02 | 6.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biomarin Pharmaceutical. More…
| Operations | Investing | Financing |
| 138.56 | -100.99 | -18.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biomarin Pharmaceutical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.76k | 1.86k | 26 |
Key Ratios Snapshot
Some of the financial key ratios for Biomarin Pharmaceutical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.4% | – | 7.2% |
| FCF Margin | ROE | ROA |
| 1.4% | 2.1% | 1.5% |
Analysis – Biomarin Pharmaceutical Intrinsic Value Calculator
As GoodWhale, we have conducted a thorough analysis of BioMarin Pharmaceutical‘s fundamentals and through our proprietary Valuation Line, determined the intrinsic value of a share to be around $97.7. This suggests that investors may be able to capitalize on good returns if the stock reaches its intrinsic value. More…
Peers
The competition in the biopharmaceutical industry is fierce, with companies like Biomarin Pharmaceutical Inc, Sangamo Therapeutics Inc, Pfizer Inc, and Sanofi SA all vying for a piece of the pie. Each company has its own unique strengths and weaknesses, and it is up to the individual investor to decide which company is the best investment.
– Sangamo Therapeutics Inc ($NASDAQ:SGMO)
Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative genomic medicines to treat serious and life-threatening diseases. The company has a market cap of $674.74 million and a negative return on equity of 32.96%. Sangamo Therapeutics is headquartered in Richmond, California.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc. is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in New York City. Pfizer is a diversified company that operates in three main business segments: Pharmaceuticals, Animal Health, and Consumer Health.
– Sanofi SA ($OTCPK:SNYNF)
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, that covers seven major therapeutic areas: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Sanofi Genzyme. As of 2020, Sanofi has 104,000 employees worldwide.
The company’s market cap is $98.97B as of 2022 and its ROE is 7.56%. Sanofi is a global leader in the pharmaceutical industry, with a strong presence in emerging markets. The company has a diversified product portfolio and is a major player in the diabetes market. Sanofi is also active in the vaccine market, with a number of innovative products in its portfolio.
Summary
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes novel therapies for patients with serious and life-threatening rare genetic diseases. Truist Financial Corp has recently disclosed that they have acquired a stake of $346000 in the company. Investors are looking positively at BioMarin as their product portfolio is expanding rapidly. The company is in the process of launching new products across multiple therapeutic areas. They are focused on initiating Phase 3 clinical trials with their latest product, vosoritide, for treating achondroplasia which is a form of dwarfism.
Additionally, BioMarin has shown success with their gene therapy product for treating a rare genetic disorder called mucopolysaccharidosis type 1. Analysts are expecting that BioMarin’s share price will increase in the coming quarters due to its strong pipeline and the potential of its products.
